title: Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria.
abstract: Tafenoquine (TQ), a new 8-aminoquinoline with activity against all stages of the Plasmodium vivax life cycle, is being developed for the radical cure of acute P. vivax malaria in combination with chloroquine. The efficacy and exposure data from a pivotal phase 2b dose-ranging study were used to conduct exposure-response analyses for TQ after administration to subjects with P. vivax malaria. TQ exposure (i.e., area under the concentration-time curve [AUC]) and region (Thailand compared to Peru and Brazil) were found to be statistically significant predictors of clinical response based on multivariate logistic regression analyses. After accounting for region/country, the odds of being relapse free at 6 months increased by approximately 51% (95% confidence intervals [CI], 25%, 82%) for each 25-U increase in AUC above the median value of 54.5 μg · h/ml. TQ exposure was also a significant predictor of the time to relapse of the infection. The final parametric, time-to-event model for the time to relapse, included a Weibull distribution hazard function, AUC, and country as covariates. Based on the model, the risk of relapse decreased by 30% (95% CI, 17% to 42%) for every 25-U increase in AUC. Monte Carlo simulations indicated that the 300-mg dose of TQ would provide an AUC greater than the clinically relevant breakpoint obtained in a classification and regression tree (CART) analysis (56.4 μg · h/ml) in more than 90% of subjects and consequently result in a high probability of being relapse free at 6 months. This model-based approach was critical in selecting an appropriate phase 3 dose. (This study has been registered at ClinicalTrials.gov under registration no. NCT01376167.).
authors.affiliation: GlaxoSmithKline Clinical Pharmacology Modeling & Simulation, King of Prussia, Pennsylvania, USA David.M.Tenero@gsk.com.
authors.forename: David
authors.initials: D
authors.lastname: Tenero
authors.affiliation: GlaxoSmithKline Clinical Development, Diseases of the Developing World, Stockley Park, United Kingdom.
authors.forename: Justin A
authors.initials: JA
authors.lastname: Green
authors.affiliation: GlaxoSmithKline Clinical Pharmacology Modeling & Simulation, King of Prussia, Pennsylvania, USA.
authors.forename: Navin
authors.initials: N
authors.lastname: Goyal
mesh_terms: D000328:Adult; D000634:Aminoquinolines / Q000627:therapeutic use*; D000962:Antimalarials / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016015:Logistic Models; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D010966:Plasmodium vivax / Q000187:drug effects / Q000472:pathogenicity; D055815:Young Adult
chemical_list: D000634:Aminoquinolines; D000962:Antimalarials; C055852:tafenoquine